Aldosterone and refractory hypertension

Moffat J Nyirenda; Paul L Padfield

doi:10.1097/MED.0b013e32814db831

Aldosterone and refractory hypertension

Moffat J Nyirenda, Paul L Padfield

School of Regeneration and Repair

Research output: Contribution to journal › Article › peer-review

Abstract

Evidence from clinical trials suggests that refractory hypertension is increasingly common. The underlying mechanisms are largely unknown but recent data have implicated increased aldosterone activity as an important mediator of resistance to routinely used antihypertensive agents.

Original language	English
Pages (from-to)	213-8
Number of pages	6
Journal	Current Opinion in Endocrinology, Diabetes and Obesity
Volume	14
Issue number	3
DOIs	https://doi.org/10.1097/MED.0b013e32814db831
Publication status	Published - 2007

Access to Document

10.1097/MED.0b013e32814db831

Cite this

@article{cc690dea6cba4e60b7ad5a6dd612b0d9,

title = "Aldosterone and refractory hypertension",

abstract = "Evidence from clinical trials suggests that refractory hypertension is increasingly common. The underlying mechanisms are largely unknown but recent data have implicated increased aldosterone activity as an important mediator of resistance to routinely used antihypertensive agents.",

author = "Nyirenda, \{Moffat J\} and Padfield, \{Paul L\}",

year = "2007",

doi = "10.1097/MED.0b013e32814db831",

language = "English",

volume = "14",

pages = "213--8",

journal = "Current Opinion in Endocrinology, Diabetes and Obesity",

issn = "1752-2978",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Aldosterone and refractory hypertension

AU - Nyirenda, Moffat J

AU - Padfield, Paul L

PY - 2007

Y1 - 2007

N2 - Evidence from clinical trials suggests that refractory hypertension is increasingly common. The underlying mechanisms are largely unknown but recent data have implicated increased aldosterone activity as an important mediator of resistance to routinely used antihypertensive agents.

AB - Evidence from clinical trials suggests that refractory hypertension is increasingly common. The underlying mechanisms are largely unknown but recent data have implicated increased aldosterone activity as an important mediator of resistance to routinely used antihypertensive agents.

U2 - 10.1097/MED.0b013e32814db831

DO - 10.1097/MED.0b013e32814db831

M3 - Article

C2 - 17940442

SN - 1752-2978

VL - 14

SP - 213

EP - 218

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

IS - 3

ER -

Aldosterone and refractory hypertension

Abstract

Access to Document

Fingerprint

Cite this